Orally disintegrating carbidopa/levodopa

• Olanow CW , WattsRL, KollerWC: An algorithm (decision tree) for the management of Parkinson‘s disease (2001): treatment guidelines.Neurology56(11), S1–S88 (2001).
   PubMed Web of Science ®Google Scholar
• Fearnley J , LeesAJ: Parkinson‘s disease: neuropathology. In:Movement Disorders: Neurologic Principles and Practice. Watts RL, Koller WC (Eds). McGraw-Hill, NY, USA, 263–278 (1997).
   Google Scholar
• Morgante  L, Rocca WA, Di Rosa AE et al.: Sicilian neuro-epidemiologic study (SNES) group. Prevalence of Parkinson‘s disease and other types of Parkinsonism: a door-to-door survey in three Sicilian municipalities. Neurology42(10), 1901–1907 (1992).
   PubMed Web of Science ®Google Scholar
• Day  JC: Population projections of the United States, by age, sex, race, and hispanic origin: 1993 to 2050. In: US Bureau of the Census, Current Population Reports. US Government Printing Office, Washington, DC, USA, 25–1104 (1993).
   Google Scholar
• Parashos SA , MaraganoreDM, O‘BrienPC, RoccaWA: Medical services utilization and prognosis in Parkinson disease: a population-based study.Mayo Clin. Proc.77(9), 918–925 (2002).
   PubMed Web of Science ®Google Scholar
• Paulson HL , SternMB: Clinical manifestations of Parkinson‘s disease. In:Movement Disorders: Neurologic Principles and Practice. Watts RL, Koller WC (Eds). McGraw-Hill, NY, USA, 81–199 (1997).
   Google Scholar
• Nelson MV , BerchouRC, LeWittPA: Parkinson‘s disease. In:Pharmacotherapy: A Pathophysiologic Approach. DiPiro JT, Talbert RL, Yee GC et al. (Eds). McGraw-Hill Companies, Inc., NY, USA, 1075–1088 (2005).
   Google Scholar
• Guttman M , KishSJ, FurukawaY: Current concepts in the diagnosis and management of Parkinson's disease.CMAJ168(5), 293–301 (2003).
   PubMed Web of Science ®Google Scholar
• Sobel N , ThomasonME, StappenIet al.: An impairment in sniffing contributes to the olfactory impairment in Parkinson's disease. Proc. Natl Acad. Sci. USA98(7), 4154–4159 (2001).
   PubMed Web of Science ®Google Scholar
• Richard IH : Anxiety disorders in Parkinson‘s disease.Adv. Neurol.96, 42–55 (2005).
   PubMedGoogle Scholar
• Hughes TA , RossHF, MusaSet al.: A 10-year study of the incidence of and factors predicting dementia in Parkinson‘s disease. Neurology54(6), 1596–1602 (2000).
   PubMedGoogle Scholar
• Practice parameters: initial therapy of Parkinson‘s disease (Summary statement): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology43(7), 1296–1297 (1993).
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group: Levodopa and the progression of Parkinson‘s disease. N. Engl. J. Med.351(24), 2498–2508 (2004).
   PubMed Web of Science ®Google Scholar
• Kurth MC , AdlerCH, HilaireMSet al.: Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology48(1), 81–87 (1997).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group: Entacopone improved motor fluctations in levodopa-treated Parkinson‘s disease patients. Ann. Neurol.42(5), 747–755 (1997).
   PubMed Web of Science ®Google Scholar
• Nutt JG , WoodwardWR, BecknerRMet al.: Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology44(5), 913–919 (1994).
   PubMed Web of Science ®Google Scholar
• Clarke CE , GuttmanM: Dopamine agonist monotherapy in Parkinson's disease.Lancet360(9347), 1767–1769 (2002).
   PubMed Web of Science ®Google Scholar
• Calne DB : Treatment of Parkinson‘s disease.N. Eng. J. Med.329(14), 1021–1027 (1993).
   PubMedGoogle Scholar
• Baseman DG , O‘SuilleabhainPE, Reimold SC, Laskar SR, Baseman MPH, Dewey RB Jr: Pergolide use in Parkinson‘s disease is associated with cardiac valve regurgitation. Neurology63(2), 301–304 (2004).
   PubMed Web of Science ®Google Scholar
• Lang AE , LozanoAM: Parkinson‘s disease – second of two parts.N. Engl. J. Med.339(16), 1130–1143 (1998).
   PubMed Web of Science ®Google Scholar
• Elizan TS , YahrMD, MorosDA, Mendoza MR, Pang S, Bodian CA: Selegiline use to prevent progression of Parkinson‘s disease. experience in 22 de novo patients. Arch. Neurol.46(12), 1275–1279, (1989).
   PubMedGoogle Scholar
• Parkinson‘s Study Group: Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann. Neurol.39(1), 29–36 (1996).
   PubMed Web of Science ®Google Scholar
• Parkinson‘s Study Group: Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann. Neurol.39(1), 37–45 (1996).
   PubMed Web of Science ®Google Scholar
• Shoulson I , OakesD, FahnSet al.: Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of Parkinsonism trial. Ann. Neurol.51(5), 604–612 (2002).
   PubMed Web of Science ®Google Scholar
• Goetz CG , KollerWC, PoeweWet al.: DA agonists – non-ergot derivatives: apomorphine. Mov. Disord.17(Suppl. 4), S83–S89 (2002).
   Google Scholar
• Stocchi F : Apomorphine and lisuride infusion. A comparative chronic study.Adv. Neurol.60, 653–655 (1993).
   PubMedGoogle Scholar
• Chaudhuri KR , CritchleyP, AbbottRJet al.: Subcutaneous apomorphine for on–off oscillations in Parkinson's disease. Lancet2(8622), 1260 (1988).
   PubMed Web of Science ®Google Scholar
• Colzi A , TurnerK, LeesAJ: Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.J. Neurol. Neurosurg. Psychiatr.64(5), 573–576 (1998).
   PubMed Web of Science ®Google Scholar
• Manson AJ , TurnerKE, LeesAJ: Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson‘s disease: long-term follow-up study of 64 patients.Mov. Disord.17(6), 1235–1241 (2002).
   PubMed Web of Science ®Google Scholar
• Neef C , van Laar T: Pharmacokinetic– pharmacodynamic relationships of apomorphine in patients with Parkinson‘s disease. Clin. Pharmacokinet.37(3), 257–271 (1999).
   PubMed Web of Science ®Google Scholar
• Nyholm D , Nilsson Remahl AIM, Dizdar Net al.: Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology64(2), 216–223 (2005).
   PubMed Web of Science ®Google Scholar
• Nilsson D , NyholmD, AquiloniusSM: Duodenal levodopa infusion in Parkinson‘s disease-long-term experience.Acta Neurol. Scand.104(6), 343–348 (2001).
   PubMed Web of Science ®Google Scholar
• Goetz CG , KollerWC, PoeweWet al.: MAO-B inhibitors for the treatment of Parkinson‘s disease. Mov. Disord.17(Suppl. 4), S38–S44 (2002).
   PubMed Web of Science ®Google Scholar
• Rabey JM , SagiI, HubermanMet al.: Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin. Neuropharmacol.23(6), 324–330 (2000).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group: A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch. Neurol.59(12), 1937–1943 (2002).
   PubMed Web of Science ®Google Scholar
• Waters CH , SethiKD, HauserRAet al.: Zydis selegiline reduces off time in Parkinson‘s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov. Disord.19(4), 426–432 (2004).
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group: A controlled trial of rotigotine monotherapy in early Parkinson‘s disease. Arch. Neurol.60(12), 1721–1728 (2003).
   PubMed Web of Science ®Google Scholar
• Leopold NA , PolanskyM, HurkaMR: Drug adherence in Parkinson‘s disease.Mov. Disord.19(50), 513–517 (2004).
   PubMedGoogle Scholar
• Dowson AJ , CharlesworthBR: Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet.Int. J. Clin. Pract.57(7), 573–576 (2003).
   PubMed Web of Science ®Google Scholar
• Voss TC , KlapperJA: Patient preference for orally dissolving rizatriptan or zolmitriptan: a comparative, open-label, randomized, crossover trial in triptan-experienced patients.Headache42, 401 (2002).
   Google Scholar
• Papavasilou PS , CotziasGC, DubySEet al.: Levodopa in parkinsonism: potentiation of central effects with a peripheral inhibitor. N. Engl. J. Med.286(1), 8–14 (1972).
   PubMed Web of Science ®Google Scholar
• Deleu D , NorthwayMG, HanssensY: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson‘s disease.Clin. Pharmacokinet.41(4), 261–309 (2002).
   PubMed Web of Science ®Google Scholar
• Jonkers N , SarreS, EbingerG, MichotteY: Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylatin in striatum of the rat.J. Neural Transm.108(5), 559–570 (2001).
   PubMed Web of Science ®Google Scholar
• Nutt JG , HolfordNHG: The response to levodopa in Parkinson‘s disease: imposing pharmacological law and order.Ann. Neurol.39(5), 561–573 (1996).
   PubMed Web of Science ®Google Scholar
• Zappia M , OliveriRL, BoscoDet al.: The long-duration response to L-dopa in the treatment of early PD. Neurology54(10), 1910–1915 (2000).
   PubMed Web of Science ®Google Scholar
• Zappia M , ColaoR, MontesantiRet al.: Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson‘s disease. Ann. Neurol.42(2), 245–248 (1997).
   PubMed Web of Science ®Google Scholar
• Stocchi F , BerardelliA, VaccaLet al.: Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease. Clin. Neuropharm.26(3), 151–155 (2003).
   PubMed Web of Science ®Google Scholar
• Iyer SS , MorganJC, SethiDK: Absorption of orally disintegrating carbidopa-levodopa requires intact small bowel function.Neurology65(9), 1507 (2005).
   PubMed Web of Science ®Google Scholar
• Rahman MK , NagatsuT, KatoT: Aromatic L-amino acid decarboxylase activity in central and peripheral tissues and serum of rats with L-dopa and L-5-hydroxytryptophan as substrates.Biochem. Pharmacol.30(6), 645–649 (1981).
   PubMed Web of Science ®Google Scholar
• Goldstein DS , EisenhoferG, KopinIJ: Sources and significance of plasma levels of catechols and their metabolites in humans.J. Pharmacol. Exp. Therap.305(3), 800–811 (2003).
   PubMed Web of Science ®Google Scholar
• Hamilton EL , LutzEM: Orally disintegrating tablets.Drug Delivery Technology5(1), 34–37 (2005).
   Google Scholar
• Nausieda PA , PfeifferRF, TagliatiM, KastenholzKV, DeRocheC, SlevinJT: A multicenter, open-label, sequential study comparing preferences for carbidopa–levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson‘s disease.Clin. Therap.27(1), 58–63 (2005).
   PubMed Web of Science ®Google Scholar
• Nutt JG : Levodopa-induced dyskinesia: review, observations, and speculations.Neurology40(2), 340–345 (1990).
   PubMed Web of Science ®Google Scholar
• Marsden CD : Late development failure – pathophysiology and management. In:20 years of Madopar – new avenues. Poewe W, Lees AJ (Eds). Editiones Roche, Basel, Switzerland, 65–76 (1993).
   Google Scholar
• Müller T , WerneB, FowlerB, KuhnW: Nigral endothelial dysfunction, homocysteine, and Parkinson‘s disease.Lancet354(9173), 126–127 (1999).
   PubMed Web of Science ®Google Scholar
• Miller JW , SelhubJ, NadeauMR, Thomas CA, Feldman RG, Wolf PA: Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology60(7), 1125–1129 (2003).
   PubMed Web of Science ®Google Scholar

Websites

• Parcopa™ Product Information. Schwarz Pharma. www.parcopa.com/PARCOPAFullPI.pdf
   Google Scholar
• Sinemet Product Information. Merck & Co. www.sinemetcr.com
   Google Scholar
• Orally disintegrating tablets, Drug Delivery Technology. www.drugdeliverytech.com/cgi-bin/articles.cgi?idArticle=309
   Google Scholar